Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab Prior to Primary PCI in STEMI
NCT06364124Recruiting
- Sponsor
- Beijing Luhe Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of evolocumab in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Beijing Luhe Hospital. Primary endpoint: Average percent change from baseline in LDL-C levels at 30 days. Started Jun 2023; status: recruiting.
02
Drugs
evolocumab
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06364124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364124.